liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis
Linköping University, Department of Clinical and Experimental Medicine, Gastroenterology and Hepatology. Linköping University, Faculty of Health Sciences.
University of Barcelona, Spain .
University of Copenhagen, Denmark .
2013 (English)In: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 37, no 8, 795-798 p.Article in journal (Refereed) Published
Abstract [en]

Background Microscopic colitis (MC) is a common chronic diarrhoeal disease, and remission can be induced with budesonide. However, diarrhoea relapses frequently when budesonide is tapered and a few patients become budesonide intolerant. Aim To examine retrospectively the effect of azathioprine (AZA) and mercaptopurine (MP) in patients with chronic, active MC. Methods/patients Data on all MC patients who received AZA or MP in the years 19972011 at three centres representing three countries were pooled for analysis. The indications for thiopurine therapy were frequent relapses after short-term treatment (N=26), budesonide dependency on 6mg (N=15) and budesonide intolerance (N=5). The response to thiopurine treatment was defined as clinical remission, intolerance or nonresponse. Results Forty-six MC patients (32 CC and 14 LC), 32 female; median age 59years (range: 3683) with a median disease duration of 3years (range: 0.518) were included. Thirteen patients (28%) achieved long-term clinical remission on AZA therapy. AZA failed in 31 patients (67%) due to intolerance and in 2 patients (4%) because of nonresponse. Thirteen of 31 AZA-intolerant patients were switched to MP and 6 patients (46%) obtained clinical remission. Thus, the overall response rate to thiopurines was 19/46 (41%). The main side effects were nausea/vomiting and abnormally elevated liver enzymes. Conclusions In this retrospective case series, the majority of chronic, active MC patients were intolerant to AZA leading to cessation of treatment. However, further studies are needed to explore the efficacy, acceptance, tolerance and safety of MP in patients with chronic, active MC refractory to budesonide.

Place, publisher, year, edition, pages
Wiley-Blackwell , 2013. Vol. 37, no 8, 795-798 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-91007DOI: 10.1111/apt.12261ISI: 000316325900004OAI: diva2:615671
Available from: 2013-04-11 Created: 2013-04-11 Last updated: 2015-03-12

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Munch, A
By organisation
Gastroenterology and HepatologyFaculty of Health Sciences
In the same journal
Alimentary Pharmacology and Therapeutics
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 29 hits
ReferencesLink to record
Permanent link

Direct link